Our portfolio


Producer of innovative elastomers for injectable medicines

  • Fund V
  • Solutions for the medical industry
  • Entry 2024
  • Exit -
  • Sales €50 million

The Switzerland-headquartered Lonstroff AG is one of the world leaders in the development and manufacturing of innovative elastomers for injectable medicines. The Company was founded in 1908 and acquired by the Japanese Sumitomo Rubber Industries (SRI) in 2015. After some challenging years impacted by COVID and the Ukraine war, SRI decided to divest its non-core business Lonstroff and sold the shares to Nimbus in Jan 2024.

The company’s primarily focus is to offer rubber packaging components to medical, biologic, generic and pharmaceutical drug customers. Lonstroff also produces rubber Laminates mostly used for transmission and conveyor belts.

Lonstroff provides solutions for the High Demanding Pharmaceutical and Medical industry, including standard innovative products and development of custom solutions. The product portfolio consists of a standard range of Vials Stoppers and Prefilled Syringe components, coated or not coated, available in Ready to Sterilize or Ready to Use solutions.
With 300 team members, three plants in Switzerland and Slovenia and one Research Centers in Switzerland, Lonstroff provides long lasting expertise in pure rubber formulations and development.

The focus for improvement with Nimbus as a new owner will be in driving operational excellence and accelerating profitable growth in higher margin business. It is Lonstroff’s vision is to become the first credible challenger for rubber component solutions in the Global Injectable Pharma Market by bringing flexibility, service and reliability to customers.

More information about this case?